A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2018

At a glance

  • Drugs Montelukast (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors IntelGenx Corp.
  • Most Recent Events

    • 10 May 2018 According to an IntelGenx Corp. media release, patient screening is expected to begin in Q2 2018.
    • 24 Jan 2018 According to an IntelGenx Corp. media release, Cogstate and JSS Medical Research as the Contract Research Organizations are supporting this trial. Patient screening is expected to begin before the end of Q1 2018.
    • 24 Jan 2018 Status changed from not yet recruiting to recruiting, according to an IntelGenx Corp. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top